Skip to Content

Insulet Corp PODD

Morningstar Rating
$167.82 −1.43 (0.84%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

PODD is trading at a 32% discount.
Price
$167.82
Fair Value
$928.00
Uncertainty
High
1-Star Price
$382.83
5-Star Price
$632.00
Economic Moat
Cccssh
Capital Allocation
Pdblnlwc

Bulls Say, Bears Say

Bulls

We see global growth for the insulin pump market, as Type 1 diabetics embrace continuous subcutaneous insulin infusion therapy for its lower rate of long-term diabetes-related complications.

Bears

With only one product and low switching costs for customers, Insulet is very vulnerable if larger competitors produce similar or superior tubeless insulin pumps.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PODD is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$169.25
Day Range
$164.43169.88
52-Week Range
$125.82335.91
Bid/Ask
$164.00 / $170.57
Market Cap
$11.73 Bil
Volume/Avg
924,272 / 928,053

Key Statistics

Price/Earnings (Normalized)
61.70
Price/Sales
7.28
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Mid Growth
Total Number of Employees
3,000

Competitors

Valuation

Metric
PODD
ABT
DXCM
Price/Earnings (Normalized)
61.7027.0481.04
Price/Book Value
16.015.3922.79
Price/Sales
7.285.2314.37
Price/Cash Flow
36.7421.5669.82
Price/Earnings
PODD
ABT
DXCM

Financial Strength

Metric
PODD
ABT
DXCM
Quick Ratio
2.361.162.39
Current Ratio
3.511.642.84
Interest Coverage
6.1410.8629.34
Quick Ratio
PODD
ABT
DXCM

Profitability

Metric
PODD
ABT
DXCM
Return on Assets (Normalized)
8.02%10.63%10.03%
Return on Equity (Normalized)
33.45%20.87%28.40%
Return on Invested Capital (Normalized)
10.07%14.81%11.06%
Return on Assets
PODD
ABT
DXCM
See how this stock stacks up to its competitors with Morningstar Investor

Medical Devices Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ABT
Abbott LaboratoriesLsvxms$208.3 Bil
SYK
Stryker CorpYrht$135.3 Bil
MDT
Medtronic PLCBbnlb$112.9 Bil
BSX
Boston Scientific CorpXrrrv$98.9 Bil
EW
Edwards Lifesciences CorpNqycqlq$52.3 Bil
DXCM
DexCom IncHknqh$47.1 Bil
ZBH
Zimmer Biomet Holdings IncTzkyy$25.7 Bil
ALGN
Align Technology IncJwphbxj$23.1 Bil
PHG
Koninklijke Philips NV ADRRwzrw$18.4 Bil

Sponsor Center